Active, not recruitingPhase 3NCT05804045
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
Studying Tenosynovial giant cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Abbisko Therapeutics Co, Ltd
- Intervention
- Pimicotinib(ABSK021)(drug)
- Enrollment
- 90 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (30)
- Precision NextGen Oncology, Beverly Hills, California, United States
- Duke University Medical Center, Durham, California, United States
- Henry Ford Health System, Detroit, Michigan, United States
- Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
- The Cleveland Clinic Foundation, Cleveland, Ohio, United States
- The Ohio State University, Columbus, Ohio, United States
- The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
- Fred Hutchinson Cancer Center, Seattle, Washington, United States
- McGill University Health Center, Montreal, Canada
- Princess Margaret Cancer Center, Toronto, Canada
- The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
- Peking University People's Hospital, Beijing, Beijing Municipality, China
- The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
- Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
- The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05804045 on ClinicalTrials.govOther trials for Tenosynovial giant cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07499362Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- RECRUITINGPHASE4NCT07315841Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor SurgeryShanghai Jiao Tong University Affiliated Sixth People's Hospital
- RECRUITINGNCT07075471Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With VimseltinibDeciphera Pharmaceuticals, LLC
- ACTIVE NOT RECRUITINGPHASE3NCT05417789Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)SynOx Therapeutics Limited
- ACTIVE NOT RECRUITINGPHASE3NCT05059262Study of Vimseltinib for Tenosynovial Giant Cell TumorDeciphera Pharmaceuticals, LLC
- ACTIVE NOT RECRUITINGPHASE2NCT04703322A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in JapanDaiichi Sankyo Co., Ltd.
- RECRUITINGNCT04635111A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) TreatmentDaiichi Sankyo
- ACTIVE NOT RECRUITINGPHASE3NCT04488822A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCTDaiichi Sankyo Co., Ltd.